Lucid Diagnostics Inc.
LUCD Healthcare Medical Devices
Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 26.7%, EPS was flat, free cash flow fell 7.04% and total debt fell 7.11%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow LUCD
Lucid Diagnostics Inc. (LUCD) EV/Sales
As of 16 October 2026, Lucid Diagnostics Inc. (LUCD) trades at a EV/Sales of 14.3×. Over the past ten years it has ranged from 0.0× (September 2022) to 73.9× (November 2022); the current reading is higher than 37% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 21.3× | 146.21% |
| FY2024 | 8.7× | (60.37%) |
| FY2023 | 21.9× | (48.54%) |
| FY2022 | 42.5× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 34.2× | 10.72% |
| Mar 2026 | 30.9× | 44.62% |
| Dec 2025 | 21.3× | 11.45% |
| Sep 2025 | 19.1× | (22.71%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTRX Quanterix Corporation compare | 0.3× |
| LUNG Pulmonx Corporation compare | 0.7× |
| OWLT Owlet, Inc. compare | 0.9× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| MXCT MaxCyte, Inc. compare | 1.2× |
| APYX Apyx Medical Corporation compare | 2.2× |
| HYPR Hyperfine, Inc. compare | 2.6× |
| LUCD Lucid Diagnostics Inc. | 14.3× |
| SERA Sera Prognostics, Inc. compare | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)